STAT3 and osteosarcoma: These findings demonstrate that the pectolinarigenin action mainly dependes on SHP-1-mediated STAT3 signaling suppression and provides solid evidence for its anti-osteosarcoma action, supporting its potential as an anticancer agent [274].